dc.contributor.author |
Cheng, Wei-Tzu |
en |
dc.contributor.author |
Rosario, Roseanne |
en |
dc.contributor.author |
Muthukaruppan, Anitadevi |
en |
dc.contributor.author |
Wilson, Michelle |
en |
dc.contributor.author |
Payne, Kathryn |
en |
dc.contributor.author |
Fong, Peter C |
en |
dc.contributor.author |
Shelling, Andrew |
en |
dc.contributor.author |
Blenkiron, Cherie |
en |
dc.date.accessioned |
2018-11-18T21:25:38Z |
en |
dc.date.issued |
2017-01 |
en |
dc.identifier.citation |
Clinical Epigenetics 9(72): 21 Jul 2017 |
en |
dc.identifier.issn |
1868-7075 |
en |
dc.identifier.uri |
http://hdl.handle.net/2292/44367 |
en |
dc.description.abstract |
The aim of this study was to explore the clinical utility of microRNAs (miRNAs) as improved markers of ovarian granulosa cell tumours (GCTs) for cancer diagnosis and prognosis prediction. Current histopathological and genetic markers, such as the presence of a FOXL2 gene mutation to distinguish between the two major subtypes are not wholly accurate and as such novel biomarkers are warranted.The miRNA expression profiles of five formalin-fixed, paraffin-embedded (FFPE) adult-GCTs and five juvenile-GCTs were assessed using Affymetrix miRNA 3.0 Arrays and compared for differential expression. Ten miRNAs were assessed in an additional 33 FFPE tumours and four normal granulosa cell samples by quantitative RT-PCR, and their expression correlated to clinical information.MicroRNA array found 37 miRNAs as differentially expressed between the two GCT subtypes (p < 0.05, fold change ≥2 and among these, miRs -138-5p, -184, -204-5p, -29c-3p, -328-3p and -501-3p were validated by RT-qPCR as differentially expressed between the two GCT subtypes (p < 0.05). In addition, the expression of miR-184 was predictive of tumour recurrence in adult-GCTs, specifically for patients diagnosed with stage I and II and stage I only disease (p < 0.001 and p < 0.05, respectively).This study is the first to report on global miRNA expression profiles of human ovarian GCTs using FFPE tumour samples. We have validated six miRNAs as novel markers for subtype classification in GCTs with low levels of miR-138-5p correlating with early tumour stage. Low miR-184 abundance was correlated with tumour recurrence in early stage adult-GCT patients as a candidate predictive biomarker. Further studies are now needed to confirm the clinical utility of these miRNAs as diagnostic and recurrence markers, and understand their possible roles in the pathogenesis of GCTs. |
en |
dc.format.medium |
Electronic-eCollection |
en |
dc.language |
eng |
en |
dc.relation.ispartofseries |
Clinical epigenetics |
en |
dc.rights |
Items in ResearchSpace are protected by copyright, with all rights reserved, unless otherwise indicated. Previously published items are made available in accordance with the copyright policy of the publisher. |
en |
dc.rights.uri |
https://researchspace.auckland.ac.nz/docs/uoa-docs/rights.htm |
en |
dc.rights.uri |
https://creativecommons.org/licenses/by/4.0/ |
en |
dc.subject |
Cell Line, Tumor |
en |
dc.subject |
Humans |
en |
dc.subject |
Granulosa Cell Tumor |
en |
dc.subject |
Neoplasm Recurrence, Local |
en |
dc.subject |
MicroRNAs |
en |
dc.subject |
Neoplasm Staging |
en |
dc.subject |
Oligonucleotide Array Sequence Analysis |
en |
dc.subject |
Gene Expression Profiling |
en |
dc.subject |
Sequence Analysis, RNA |
en |
dc.subject |
DNA Methylation |
en |
dc.subject |
Gene Expression Regulation, Neoplastic |
en |
dc.subject |
Adult |
en |
dc.subject |
Child |
en |
dc.subject |
Female |
en |
dc.subject |
Biomarkers, Tumor |
en |
dc.title |
MicroRNA profiling of ovarian granulosa cell tumours reveals novel diagnostic and prognostic markers. |
en |
dc.type |
Journal Article |
en |
dc.identifier.doi |
10.1186/s13148-017-0372-0 |
en |
pubs.begin-page |
72 |
en |
pubs.volume |
9 |
en |
dc.rights.holder |
Copyright: The authors |
en |
dc.identifier.pmid |
28736583 |
en |
pubs.publication-status |
Published |
en |
dc.rights.accessrights |
http://purl.org/eprint/accessRights/OpenAccess |
en |
pubs.subtype |
Research Support, Non-U.S. Gov't |
en |
pubs.subtype |
research-article |
en |
pubs.subtype |
Journal Article |
en |
pubs.elements-id |
644699 |
en |
pubs.org-id |
Medical and Health Sciences |
en |
pubs.org-id |
Medical Sciences |
en |
pubs.org-id |
Molecular Medicine |
en |
pubs.org-id |
Oncology |
en |
pubs.org-id |
School of Medicine |
en |
pubs.org-id |
Obstetrics and Gynaecology |
en |
dc.identifier.eissn |
1868-7083 |
en |
pubs.record-created-at-source-date |
2017-07-25 |
en |
pubs.dimensions-id |
28736583 |
en |